Anacor Pharma (ANAC) Misses Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Anacor Pharmaceuticals Reports 2015 Fourth Quarter and Year-End Financial Results
February 29, 2016 4:01 PM ESTSubmitted NDA to the FDA on January 7, 2016 seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults Recognized $69.7 million in total KERYDIN® distribution and commercialization agreement revenues for the year ended December 31, 2015
PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced its financial results for the fourth quarter and year ended December 31, 2015.
The past year has been very productive... More
